U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Hypocholesterolemia

MedGen UID:
57479
Concept ID:
C0151718
Disease or Syndrome
Synonyms: Decreased circulating cholesterol level; Hypocholesteremia
SNOMED CT: Hypocholesterolemia (61336008); Hypocholesteremia (61336008)
 
HPO: HP:0003146

Definition

An decreased concentration of cholesterol in the blood. [from HPO]

Conditions with this feature

Dubowitz syndrome
MedGen UID:
59797
Concept ID:
C0175691
Disease or Syndrome
Dubowitz syndrome (DS) is a rare multiple congenital syndrome characterized primarly by growth retardation, microcephaly, distinctive facial dysmorphism, cutaneous eczema, a mild to severe intellectual deficit and genital abnormalities.
Smith-Lemli-Opitz syndrome
MedGen UID:
61231
Concept ID:
C0175694
Disease or Syndrome
Smith-Lemli-Opitz syndrome (SLOS) is a congenital multiple-anomaly / cognitive impairment syndrome caused by an abnormality in cholesterol metabolism resulting from deficiency of the enzyme 7-dehydrocholesterol (7-DHC) reductase. It is characterized by prenatal and postnatal growth restriction, microcephaly, moderate-to-severe intellectual disability, and multiple major and minor malformations. The malformations include distinctive facial features, cleft palate, cardiac defects, underdeveloped external genitalia in males, postaxial polydactyly, and 2-3 syndactyly of the toes. The clinical spectrum is wide; individuals with normal development and only minor malformations have been described.
PMM2-congenital disorder of glycosylation
MedGen UID:
138111
Concept ID:
C0349653
Disease or Syndrome
PMM2-CDG, the most common of a group of disorders of abnormal glycosylation of N-linked oligosaccharides, is divided into three clinical stages: infantile multisystem, late-infantile and childhood ataxia–intellectual disability, and adult stable disability. The clinical manifestations and course are highly variable, ranging from infants who die in the first year of life to mildly affected adults. Clinical findings tend to be similar in sibs. In the infantile multisystem presentation, infants show axial hypotonia, hyporeflexia, esotropia, and developmental delay. Feeding problems, vomiting, faltering growth, and developmental delay are frequently seen. Subcutaneous fat may be excessive over the buttocks and suprapubic region. Two distinct clinical courses are observed: (1) a nonfatal neurologic course with faltering growth, strabismus, developmental delay, cerebellar hypoplasia, and hepatopathy in infancy followed by neuropathy and retinitis pigmentosa in the first or second decade; and (2) a more severe neurologic-multivisceral course with approximately 20% mortality in the first year of life. The late-infantile and childhood ataxia–intellectual disability stage, which begins between ages three and ten years, is characterized by hypotonia, ataxia, severely delayed language and motor development, inability to walk, and IQ of 40 to 70; other findings include seizures, stroke-like episodes or transient unilateral loss of function, coagulopathy, retinitis pigmentosa, joint contractures, and skeletal deformities. In the adult stable disability stage, intellectual ability is stable; peripheral neuropathy is variable, progressive retinitis pigmentosa and myopia are seen, thoracic and spinal deformities with osteoporosis worsen, and premature aging is observed; females may lack secondary sexual development and males may exhibit decreased testicular volume. Hypogonadotropic hypogonadism and coagulopathy may occur. The risk for deep venous thrombosis is increased.
Chylomicron retention disease
MedGen UID:
208651
Concept ID:
C0795956
Disease or Syndrome
Chylomicron retention disease (CMRD), characterized by the inability to secrete chylomicrons from the enterocytes following the ingestion of fat, typically presents in infancy with failure to thrive, diarrhea, vomiting, abdominal distention, and malabsorption of fat. This leads to steatorrhea – the severity of which relates to the fat content of the diet – and in some cases, hepatomegaly. Organ systems outside of the gastrointestinal tract may also be affected (often due to malnutrition and deficiencies of fat-soluble vitamins), including neuromuscular abnormalities (typically in the first or second decade of life) secondary to vitamin E deficiency, poor bone mineralization and delayed bone maturation due to vitamin D deficiency, prolonged international normalized ratio (INR) due to vitamin K deficiency, mild ophthalmologic issues (e.g., micronystagmus, delayed dark adaptation, abnormal visual evoked potentials, and abnormal scotopic electroretinograms), and (in a small proportion of adults) cardiomyopathy with decreased ejection fraction. Affected individuals typically have marked hypocholesterolemia, low plasma apolipoprotein B levels, normal-to-low plasma triglyceride levels, and low serum concentrations of fat-soluble vitamins (A, D, E, and K). Endoscopy typically demonstrates a gelée blanche ("white hoar frosting") appearance of the duodenal mucosa.
Congenital bile acid synthesis defect 1
MedGen UID:
335883
Concept ID:
C1843116
Disease or Syndrome
Congenital defects of bile acid synthesis are autosomal recessive disorders characterized by neonatal onset of progressive liver disease with cholestatic jaundice and malabsorption of lipids and lipid-soluble vitamins from the gastrointestinal tract resulting from a primary failure to synthesize bile acids. Affected infants show failure to thrive and secondary coagulopathy. In most forms of the disorder, there is a favorable response to oral bile acid therapy (summary by Cheng et al., 2003). Genetic Heterogeneity of Congenital Defects in Bile Acid Synthesis There are several disorders that result from defects in bile acid synthesis. See CBAS2 (235555), caused by mutation in the delta(4)-3-oxosteroid 5-beta-reductase gene (AKR1D1; 604741) on chromosome 7q33; CBAS3 (613812), caused by mutation in the 7-alpha hydroxylase gene (CYP7B1; 603711) on chromosome 8q12; CBAS4 (214950), caused by mutation in the AMACR gene (604489) on chromosome 5p13; CBAS5 (616278), caused by mutation in the ABCD3 gene (170995) on chromosome 1p21; and CBAS6 (617308), caused by mutation in the ACOX2 gene (601641) on chromosome 3p14. See also progressive familial intrahepatic cholestasis (PFIC1; 211600), which has a similar phenotype.
Oculocerebrofacial syndrome, Kaufman type
MedGen UID:
343403
Concept ID:
C1855663
Disease or Syndrome
Kaufman oculocerebrofacial syndrome (KOS) is characterized by developmental delay, severe intellectual disability, and distinctive craniofacial features. Most affected children have prenatal-onset microcephaly, hypotonia, and growth deficiency. Feeding issues, ocular abnormalities, hearing impairment, and respiratory tract abnormalities are common. Ocular abnormalities can include structural abnormalities (microcornea or microphthalmia, coloboma, optic nerve hypoplasia), refractive errors (myopia ± astigmatism, hyperopia), strabismus, and entropion. Both conductive and sensorineural hearing loss have been reported as well as mixed conductive-sensorineural hearing loss of variable severity. Breathing problems can lead to prolonged hospitalization after birth in more than half of individuals. Less common findings include ectodermal abnormalities, cardiac manifestations, urogenital abnormalities, seizures, and skeletal abnormalities.
Gaucher disease due to saposin C deficiency
MedGen UID:
350479
Concept ID:
C1864651
Disease or Syndrome
Any Gaucher disease in which the cause of the disease is a mutation in the PSAP gene.
ALG9 congenital disorder of glycosylation
MedGen UID:
443955
Concept ID:
C2931006
Disease or Syndrome
Congenital disorders of glycosylation (CDGs) that represent defects of dolichol-linked oligosaccharide assembly are classified as CDG type I. For a general description and a discussion of the classification of CDGs, see CDG1A (212065).
Potocki-Lupski syndrome
MedGen UID:
444010
Concept ID:
C2931246
Disease or Syndrome
Potocki-Lupski syndrome (PTLS) is characterized by cognitive, behavioral, and medical manifestations. Cognitively, most individuals present with developmental delay, later meeting criteria for moderate intellectual disability. Behaviorally, issues with attention, hyperactivity, withdrawal, and anxiety may be seen. Some individuals meet criteria for autism spectrum disorder. Medically, hypotonia, oropharyngeal dysphagia leading to failure to thrive, congenital heart disease, hypoglycemia associated with growth hormone deficiency, and mildly dysmorphic facial features are observed. Medical manifestations typically lead to identification of PTLS in infancy; however, those with only behavioral and cognitive manifestations may be identified in later childhood.
Pancreatic triacylglycerol lipase deficiency
MedGen UID:
482157
Concept ID:
C3280527
Disease or Syndrome
Congenital pancreatic lipase deficiency is a rare, monoenzymatic form of exocrine pancreatic failure. All reported patients have presented with similar symptoms and clinical findings, including oily/greasy stools from infancy or early childhood and the absence of discernible pancreatic disease. Failure to thrive has not been observed. Analyses of duodenal contents consistently show a marked decrease of pancreatic lipolytic activity (summary by Figarella et al., 1980).
Peroxisome biogenesis disorder type 3B
MedGen UID:
763607
Concept ID:
C3550693
Disease or Syndrome
Zellweger spectrum disorder (ZSD) is a phenotypic continuum ranging from severe to mild. While individual phenotypes (e.g., Zellweger syndrome [ZS], neonatal adrenoleukodystrophy [NALD], and infantile Refsum disease [IRD]) were described in the past before the biochemical and molecular bases of this spectrum were fully determined, the term "ZSD" is now used to refer to all individuals with a defect in one of the ZSD-PEX genes regardless of phenotype. Individuals with ZSD usually come to clinical attention in the newborn period or later in childhood. Affected newborns are hypotonic and feed poorly. They have distinctive facies, congenital malformations (neuronal migration defects associated with neonatal-onset seizures, renal cysts, and bony stippling [chondrodysplasia punctata] of the patella[e] and the long bones), and liver disease that can be severe. Infants with severe ZSD are significantly impaired and typically die during the first year of life, usually having made no developmental progress. Individuals with intermediate/milder ZSD do not have congenital malformations, but rather progressive peroxisome dysfunction variably manifest as sensory loss (secondary to retinal dystrophy and sensorineural hearing loss), neurologic involvement (ataxia, polyneuropathy, and leukodystrophy), liver dysfunction, adrenal insufficiency, and renal oxalate stones. While hypotonia and developmental delays are typical, intellect can be normal. Some have osteopenia; almost all have ameleogenesis imperfecta in the secondary teeth.
Familial hypobetalipoproteinemia 1
MedGen UID:
1639219
Concept ID:
C4551990
Disease or Syndrome
Individuals with biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) may present from infancy through to adulthood with a range of clinical symptoms including deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction. Affected individuals typically have plasma total cholesterol, LDL cholesterol, and apo B levels below the fifth centile for age and sex. Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found. The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency. In the absence of treatment, affected individuals can develop atypical pigmentation of the retina; progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors; and steatohepatitis, fibrosis, and rarely, cirrhosis of the liver. Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis. However, about 5%-10% of individuals with heterozygous APOB-FHBL develop relatively more severe nonalcoholic steatohepatitis requiring medical attention and occasionally progressing to cirrhosis, albeit very rarely.
Squalene synthase deficiency
MedGen UID:
1648421
Concept ID:
C4748427
Disease or Syndrome
Squalene synthase deficiency (SQSD) is a rare inborn error of cholesterol biosynthesis with multisystem clinical manifestations similar to Smith-Lemli-Optiz syndrome. Key clinical features include facial dysmorphism, a generalized seizure disorder presenting in the neonatal period, nonspecific structural brain malformations, cortical visual impairment, optic nerve hypoplasia, profound developmental delay / intellectual disability, dry skin with photosensitivity, and genital malformations in males.
Pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal
MedGen UID:
1716458
Concept ID:
C5394137
Disease or Syndrome
Neonatal lethal pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome (PHRINL) is an autosomal recessive multisystem disorder with onset in utero and death in the neonatal period. Rare patients may survive a few months. Affected infants show respiratory insufficiency and almost no spontaneous movement at birth, usually requiring mechanical ventilation and admission to the neonatal intensive care unit. Additional features include corneal clouding, seizures, dysmorphic facies, contractures, and progressive pontocerebellar hypoplasia with simplified gyral pattern and white matter abnormalities. Some patients may have cardiac anomalies or cardiac hypertrophy. Laboratory studies show evidence consistent with mitochondrial defects and/or abnormal cholesterol or lipid metabolism. Depending on the type of mutation or deletion, some patients may have a less severe disorder (see GENOTYPE/PHENOTYPE CORRELATIONS) (summary by Desai et al., 2017).
Microcephaly-congenital cataract-psoriasiform dermatitis syndrome
MedGen UID:
1798933
Concept ID:
C5567510
Disease or Syndrome
Microcephaly, congenital cataract, and psoriasiform dermatitis (MCCPD) represents an inborn error of cholesterol metabolism that is characterized by accumulation of a large amount of methylsterols, particularly dimethylsterols, in affected patients. The associated features of immune dysregulation, skin disease, and growth delay can be at least partially corrected with cholesterol and statin supplements (He et al., 2014).
Familial apolipoprotein gene cluster deletion syndrome
MedGen UID:
1824091
Concept ID:
C5774318
Disease or Syndrome
Apolipoprotein (apo) A-I is the major protein of HDL cholesterol, whereas apoC-III and apoA-IV are minor components. The genes coding for apoA-I, apoC-III, and apoA-IV are adjacent to one another on the long arm of chromosome 11. Familial apolipoprotein gene cluster deletion syndrome has been described in 1 family and found to be a homozygous deletion of the entire APOA1/C3/A4 gene complex. This results in a lack of expression of these plasma lipoproteins, with marked HDL-C deficiency in the homozygote and approximately half-normal levels of these apolipoproteins and HDL-C in the heterozygotes.

Professional guidelines

PubMed

Gill PK, Hegele RA
Expert Rev Endocrinol Metab 2023 May;18(3):241-253. Epub 2023 Apr 23 doi: 10.1080/17446651.2023.2204932. PMID: 37089071
Bredefeld C, Hussain MM, Averna M, Black DD, Brin MF, Burnett JR, Charrière S, Cuerq C, Davidson NO, Deckelbaum RJ, Goldberg IJ, Granot E, Hegele RA, Ishibashi S, Karmally W, Levy E, Moulin P, Okazaki H, Poinsot P, Rader DJ, Takahashi M, Tarugi P, Traber MG, Di Filippo M, Peretti N
J Clin Lipidol 2022 Nov-Dec;16(6):797-812. Epub 2022 Sep 29 doi: 10.1016/j.jacl.2022.08.009. PMID: 36243606
Lee J, Hegele RA
J Inherit Metab Dis 2014 May;37(3):333-9. Epub 2013 Nov 28 doi: 10.1007/s10545-013-9665-4. PMID: 24288038

Recent clinical studies

Etiology

Gill PK, Hegele RA
Expert Rev Endocrinol Metab 2023 May;18(3):241-253. Epub 2023 Apr 23 doi: 10.1080/17446651.2023.2204932. PMID: 37089071
Lubert AM, Alsaied T, Palermo JJ, Anwar N, Urbina EM, Brown NM, Alexander C, Almeneisi H, Wu F, Leventhal AR, Aldweib N, Mendelson M, Opotowsky AR
J Am Heart Assoc 2021 Apr 6;10(7):e019578. Epub 2021 Mar 31 doi: 10.1161/JAHA.120.019578. PMID: 33787283Free PMC Article
Moutzouri E, Elisaf M, Liberopoulos EN
Curr Vasc Pharmacol 2011 Mar;9(2):200-12. doi: 10.2174/157016111794519354. PMID: 20626336
Alves Cde A, Lima DS
J Bras Pneumol 2008 Oct;34(10):829-37. doi: 10.1590/s1806-37132008001000012. PMID: 19009217
Hauben M
Pharmacotherapy 1996 Jul-Aug;16(4):576-83. PMID: 8840363

Diagnosis

Bredefeld C, Hussain MM, Averna M, Black DD, Brin MF, Burnett JR, Charrière S, Cuerq C, Davidson NO, Deckelbaum RJ, Goldberg IJ, Granot E, Hegele RA, Ishibashi S, Karmally W, Levy E, Moulin P, Okazaki H, Poinsot P, Rader DJ, Takahashi M, Tarugi P, Traber MG, Di Filippo M, Peretti N
J Clin Lipidol 2022 Nov-Dec;16(6):797-812. Epub 2022 Sep 29 doi: 10.1016/j.jacl.2022.08.009. PMID: 36243606
Hofmaenner DA, Kleyman A, Press A, Bauer M, Singer M
Am J Respir Crit Care Med 2022 Feb 15;205(4):388-396. doi: 10.1164/rccm.202105-1197TR. PMID: 34715007Free PMC Article
Lubert AM, Alsaied T, Palermo JJ, Anwar N, Urbina EM, Brown NM, Alexander C, Almeneisi H, Wu F, Leventhal AR, Aldweib N, Mendelson M, Opotowsky AR
J Am Heart Assoc 2021 Apr 6;10(7):e019578. Epub 2021 Mar 31 doi: 10.1161/JAHA.120.019578. PMID: 33787283Free PMC Article
Moutzouri E, Elisaf M, Liberopoulos EN
Curr Vasc Pharmacol 2011 Mar;9(2):200-12. doi: 10.2174/157016111794519354. PMID: 20626336
Alves Cde A, Lima DS
J Bras Pneumol 2008 Oct;34(10):829-37. doi: 10.1590/s1806-37132008001000012. PMID: 19009217

Therapy

Gill PK, Hegele RA
Can J Cardiol 2023 Dec;39(12):1913-1930. Epub 2023 Aug 9 doi: 10.1016/j.cjca.2023.08.003. PMID: 37562541
Hofmaenner DA, Kleyman A, Press A, Bauer M, Singer M
Am J Respir Crit Care Med 2022 Feb 15;205(4):388-396. doi: 10.1164/rccm.202105-1197TR. PMID: 34715007Free PMC Article
Lubert AM, Alsaied T, Palermo JJ, Anwar N, Urbina EM, Brown NM, Alexander C, Almeneisi H, Wu F, Leventhal AR, Aldweib N, Mendelson M, Opotowsky AR
J Am Heart Assoc 2021 Apr 6;10(7):e019578. Epub 2021 Mar 31 doi: 10.1161/JAHA.120.019578. PMID: 33787283Free PMC Article
Badjatia N, Rosand J
Neurologist 2005 Nov;11(6):311-24. doi: 10.1097/01.nrl.0000178757.68551.26. PMID: 16286875
Hauben M
Pharmacotherapy 1996 Jul-Aug;16(4):576-83. PMID: 8840363

Prognosis

Gill PK, Hegele RA
Expert Rev Endocrinol Metab 2023 May;18(3):241-253. Epub 2023 Apr 23 doi: 10.1080/17446651.2023.2204932. PMID: 37089071
Hofmaenner DA, Kleyman A, Press A, Bauer M, Singer M
Am J Respir Crit Care Med 2022 Feb 15;205(4):388-396. doi: 10.1164/rccm.202105-1197TR. PMID: 34715007Free PMC Article
Lubert AM, Alsaied T, Palermo JJ, Anwar N, Urbina EM, Brown NM, Alexander C, Almeneisi H, Wu F, Leventhal AR, Aldweib N, Mendelson M, Opotowsky AR
J Am Heart Assoc 2021 Apr 6;10(7):e019578. Epub 2021 Mar 31 doi: 10.1161/JAHA.120.019578. PMID: 33787283Free PMC Article
Lee J, Hegele RA
J Inherit Metab Dis 2014 May;37(3):333-9. Epub 2013 Nov 28 doi: 10.1007/s10545-013-9665-4. PMID: 24288038
Badjatia N, Rosand J
Neurologist 2005 Nov;11(6):311-24. doi: 10.1097/01.nrl.0000178757.68551.26. PMID: 16286875

Clinical prediction guides

Armonis C, Komnianou K, Grigoropoulou P, Fragkou A, Kyritsi E, Tousoulis D, Toutouzas K
Clin Nutr ESPEN 2023 Dec;58:362-367. Epub 2023 Nov 9 doi: 10.1016/j.clnesp.2023.10.036. PMID: 38057028
Mogensen PR, Grell K, Schmiegelow K, Overgaard UM, Wolthers BO, Mogensen SS, Vaag A, Frandsen TL
PLoS One 2020;15(4):e0231209. Epub 2020 Apr 6 doi: 10.1371/journal.pone.0231209. PMID: 32251440Free PMC Article
Privitera G, Spadaro L, Marchisello S, Fede G, Purrello F
Dig Dis Sci 2018 Jan;63(1):16-26. Epub 2017 Nov 25 doi: 10.1007/s10620-017-4862-x. PMID: 29177578
Kanda T, Moriyama M
World J Gastroenterol 2017 Aug 21;23(31):5645-5649. doi: 10.3748/wjg.v23.i31.5645. PMID: 28883690Free PMC Article
Vyroubal P, Chiarla C, Giovannini I, Hyspler R, Ticha A, Hrnciarikova D, Zadak Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008 Dec;152(2):181-9. doi: 10.5507/bp.2008.029. PMID: 19219206

Recent systematic reviews

Lorenzi M, Ambegaonkar B, Baxter CA, Jansen J, Zoratti MJ, Davies G
Clin Res Cardiol 2019 May;108(5):487-509. Epub 2018 Oct 9 doi: 10.1007/s00392-018-1379-z. PMID: 30302558
Golucci APBS, Marson FAL, Ribeiro AF, Nogueira RJN
Nutrition 2018 Nov;55-56:7-14. Epub 2018 May 9 doi: 10.1016/j.nut.2018.04.007. PMID: 29960160

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...